Abstract
Fragment screening has emerged as an important tool in the pipeline of drug discovery. By using compounds of low molecular weight, it is possible to cover a broader range of the chemical space with fewer compounds. Fragments often bind with better ligand efficiencies than traditional screening and hits are capable of binding to a larger number of proteins than conventional 'drug-size' com…